Early-stage biotech has become increasingly attractive for large corporate biotech and pharma companies looking to gain a competitive edge by enhancing their development and pipeline portfolios. These partnerships have significant advantages for startups in terms of capital raises and leveraging deep corporate expertise to de-risk therapeutic developments startups are aiming to advance to market.
Join us for a conversation with Chandra Ghose-Paul, founder of BioHarmony. She will share her journey successfully closing a deal with a strategic partner Boehringer Ingelheim. Junjun Gao, Associate Director of External Innovation at Boehringer Ingelheim, joins to share corporate viewpoint. Veteran Business Development executive Brendan Rae moderates.
The event will take place virtually, on the Airmeet platfom.